In total, we found that mutation of ALKBH5 is only 1.5% in ovarian cancer, however, the mutation of IGF2BP2 accounts for 27% of ovarian cancer patients (Fig. 6C). This evidence concerns the gene IGF2BP2 and ovarian carcinoma.